← back to search

Ang Li

China Coal Research Institute (China) · US
Area of research
Oncology · Surgery
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Pancreatitis Pathology and Treatment, Esophageal Cancer Research and Treatment, and Cancer Immunotherapy and Biomarkers.
h-index
26
citations
5,165
works
171
NIH funding
primary concept
Medicine
email

Recent publications

Human-Derived Proteome Characterization of Tongue Coating in Colorectal Cancer
Journal of Proteome Research 2025cited by 1position: middledoi
Utilizing MXene-mediated electron transfer pathway to boost peroxymonosulfate activation for water purification
Separation and Purification Technology 2024cited by 24position: middledoi
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
Therapeutic Advances in Medical Oncology 2022cited by 6position: middledoi
TLR4 regulatory region variants reduce the susceptibility of small-cell lung cancer in Chinese population
European Journal of Cancer Prevention 2022cited by 5position: middledoi
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Journal of Clinical Oncology 2021cited by 650position: middledoi
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Lung Cancer 2020cited by 60position: middledoi
Abstract CT218: Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) for Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870
Cancer Research 2020cited by 2position: middledoi
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
The Lancet Oncology 2019cited by 365position: middledoi
Significance of Combined Preoperative Serum ALB and DNLR For Diagnosis of Pancreatic Cancer
Future Oncology 2018cited by 43position: middledoi
The Diagnostic Role of Circulating Inflammation-Based Biomarker in Gallbladder Carcinoma
Biomarkers in Medicine 2018cited by 17position: middledoi
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Journal of Clinical Oncology 2017cited by 872position: middledoi

Grants

Collaborative Research: CISE MSI: RDP: III: Physics-Guided Generative Artificial Intelligence for Inverting Chaotic Advection-Diffusion Dynamics
NSF2431611$300,0002024–2027PIRePORTER

Frequent collaborators

Jie Wang · Qiqihar University3 papers (2020–2022)Yi‐Long Wu · China Agricultural University3 papers (2020–2022)Jianhua Chang · Nanjing University of Posts and Telecommunications3 papers (2020–2022)Zhiyong Ma · Chinese Academy of Medical Sciences & Peking Union Medical College3 papers (2020–2022)Shun Lü · Central South University3 papers (2020–2022)Jianying Zhou · Jilin University3 papers (2020–2022)Ying Cheng · Changzhi University3 papers (2020–2022)Lin Wu · Central South University3 papers (2020–2022)Changli Wang · Second Military Medical University2 papers (2020–2022)Jun Zhao · Beijing Institute of Technology2 papers (2020–2022)Jifeng Feng · Zhejiang Cancer Hospital2 papers (2020–2022) · 2 papers (2020–2022)Shucai Zhang · Northeastern University2 papers (2020–2022)Mengzhao Wang · Beijing Chest Hospital2 papers (2020–2022)Baocheng Wang · Jinan University2 papers (2020–2022)Gongyan Chen · Harbin Medical University2 papers (2020–2022)Linying Zhou · Nanchang University2 papers (2018–2018)Hou‐Qun Ying · Guangzhou University of Chinese Medicine2 papers (2018–2018)Xiao Zhen Wang · Nanchang University2 papers (2018–2018)Kewei Ma · McGill University Health Centre2 papers (2020–2022)